Response
To the Editor:
We appreciate the concern that our results 1 contradict a previous study by Iribarren et al 2 that found an association between elevated blood lipid levels and reduced hospitalization and mortality from pneumonia/influenza and COPD. However, their study used a cross-sectional design, a weaker design for evaluating causal associations. Also, most of the results were not statistically significant and were inconsistent across strata of gender and age. They concluded that their results might be spurious or even secondary to reverse causality. If high blood lipid levels are protective against morbidity and mortality from COPD and influenza/pneumonia, then the lipid-reducing effect of statins should have resulted in higher rates of hospitalization and mortality in our statin users.
Drs. Vos and Mascitelli also suggest that randomized trials have already been completed. However, the prescribing information for ezetimibe/simvastatin did not demonstrate an association between simvistatin use and the incidence of influenza in a clinical trial. 3 Among those receiving simvistatin, 24 of 1,234 patients (1.9%) had influenza diagnosed, compared with 3 of 311 patients (1.0%) who received placebo (p ϭ 0.33, Fisher exact test). Lower respiratory infections were not reported.
We are unable to rule out residual confounding by a "healthyuser" effect due to our limited data. However, we do not believe that it can completely account for the very strong protective effect that we identified, especially in preventing deaths associated with COPD. In our study, like many other observational studies of the effects of statin use, statin users compared to nonusers were somewhat older and had more comorbidities. This is a seemingly paradoxical finding when implicating a healthy-user effect. One of the reasons we recommend randomized clinical trials to study the pleiotropic effects of statins in COPD and influenza is to help prevent confounding by a possible healthy-user effect.
Floyd Frost, PhD Lovelace Respiratory Research Unit
Albuquerque, NM 
Mechanism of Statin-Associated Mortality Reduction in COPD
We read with interest the article by Frost et al (April 2007) 1 reporting reduced mortality in COPD patients prescribed statins. The antiinflammatory properties of these drugs hold exciting promise in respiratory disease, especially COPD, in which there is heightened systemic inflammation associated with increased cardiovascular morbidity. 2 There are currently no randomized trials of statins in COPD, and the mechanism underlying any mortality benefit remains unexplained. We recently performed a study 3 of systemic biomarkers in patients with COPD, and have now analyzed these data with respect to the presence of cardiovascular disease (CVD) and prescription of statins on plasma interleukin (IL)-6 and C-reactive protein (CRP).
Plasma biomarkers were assayed in samples from 90 patients with stable COPD (mean age, 70.1 years [SD, 8.2 years]; median FEV 1 , 1.00 L (range, 0.74 to 1.33 L); median FEV 1 , 43.9% of predicted (range, 27.5 to 56.8% of predicted). 3 Self-reported CVD (angina, myocardial infarction, cerebrovascular disease, and/or peripheral vascular disease) and prescription of statins were recorded at clinic visits within 6 months of the samples (available in 87 of 90 patients).
Sixteen patients (18%) had CVD, of whom 7 patients (44%) were receiving statins. Of the 71 patients (82%) without CVD, 12 patients (17%) were receiving statins. Age, FEV 1 , exacerbation frequency, and inhaled steroid dose did not vary between patients with and without CVD, or who were and were not prescribed statins.
As expected, in COPD patients not receiving statins, those with CVD had a higher plasma IL-6 concentration than those without CVD: median, 3.02 pg/mL vs 1.49 pg/mL (p ϭ 0.022). Furthermore, patients with COPD and CVD who were prescribed statins had lower plasma IL-6 concentrations than those not receiving these drugs: 1.43 pg/mL vs 3.02 pg/mL (p ϭ 0.031). However, plasma IL-6 concentrations were not significantly different in COPD patients without CVD in the presence or absence of statins: 1.11 pg/mL vs 1.49 pg/mL (p ϭ 0.187). There were no differences with respect to CRP.
In conclusion, while statins were associated with reduced plasma IL-6 concentration in patients with COPD and comorbid CVD, this may not be true in patients without CVD. This observation may be important in the interpretation of clinical trials of statins in patients with COPD.
